2010 in cancer

FDA · US: 29 records / 19 drugsEMA · EU: 9 records / 7 drugsHealth Canada · CA: 9 records / 6 drugs

• Nov 15, 2010Eribulin FDA · US original application approved LiposarcomaUnresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.openfda
• Nov 15, 2010Eribulin FDA · US original application approved Malignant Breast NeoplasmMetastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have…openfda
• Jun 17, 2010Cabazitaxel FDA · US original application approved Castration-Resistant Prostate CarcinomaJEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated…openfda
• Jun 1, 2010Denosumab FDA · US original application approved Malignant Prostate Neoplasmto increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate canceropenfda
• Jun 1, 2010Denosumab FDA · US original application approved Malignant Breast Neoplasmto increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast canceropenfda
• Mar 10, 2010Triptorelin FDA · US original application approved Malignant Prostate NeoplasmTRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. TRELSTAR is a gonadotropin releasing hormone (GnRH) agonist…openfda
• Jun 1, 2010Denosumab FDA · US original application approved cancer not stated in this recordof postmenopausal women with osteoporosis at high risk for fracture • to increase bone mass in men with osteoporosis at high risk for fracture • of…openfda
• Apr 20, 2010Everolimus FDA · US original application approved cancer not stated in this recordKidney Transplant : at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids • Liver Transplant…openfda
• Mar 25, 2010Imiquimod FDA · US original application approved cancer not stated in this recordZYCLARA 2.5% and 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp…openfda
• Mar 15, 2010Temozolomide EMA · EU centralised approved GlioblastomaFor the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy…ema
• Jan 28, 2010Temozolomide EMA · EU centralised approved GlioblastomaFor the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy…ema
• Jan 25, 2010Temozolomide EMA · EU centralised approved GlioblastomaTemomedac hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and…ema
• Nov 18, 2010Denosumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-11-18 (see label)openfda
• Oct 29, 2010Everolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-10-29 (see label)openfda
• Oct 28, 2010Dasatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-10-28 (see label)openfda
• Oct 28, 2010Dasatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-10-28 (see label)openfda
• Oct 21, 2010Bicalutamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as JAMP BICALUTAMIDE (DIN 02357216) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• Oct 20, 2010Trastuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-10-20 (see label)openfda
• Oct 12, 2010Lenalidomide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-10-12 (see label)openfda
• Sep 24, 2010Dexamethasone FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-09-24 (see label)openfda
• Sep 17, 2010Ibandronic Acid EMA · EU centralised approved cancer not stated in this recordIbandronic acid 50mg Ibandronic Acid Teva is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy…ema
• Sep 9, 2010Fulvestrant FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-09-09 (see label)openfda
• Aug 13, 2010Pazopanib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as VOTRIENT (DIN 02352303) under ATC L01EX03 PAZOPANIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Aug 5, 2010Trabectedin Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as YONDELIS (DIN 02351528) under ATC L01CX01 TRABECTEDIN. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jul 9, 2010Temsirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-07-09 (see label)openfda
• Jul 1, 2010Sunitinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-07-01 (see label)openfda
• Jun 17, 2010Nilotinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-06-17 (see label)openfda
• Jun 14, 2010Pazopanib EMA · EU centralised approved cancer not stated in this recordRenal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have…ema
• Jun 9, 2010Topotecan EMA · EU centralised approved cancer not stated in this recordTopotecan monotherapy is indicated for the treatment of patients with relapsed small-cell lung cancer (SCLC) for whom re-treatment with the first-line regimen…ema
• Jun 7, 2010Filgrastim EMA · EU centralised approved cancer not stated in this recordFilgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established…ema
• May 26, 2010Denosumab EMA · EU centralised approved cancer not stated in this recordTreatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of…ema
• May 13, 2010Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-05-13 (see label)openfda
• May 5, 2010Bicalutamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ACH-BICALUTAMIDE (DIN 02325985) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• May 3, 2010Letrozole Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ACH-LETROZOLE (DIN 02338459) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
• Apr 30, 2010Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-04-30 (see label)openfda
• Apr 28, 2010Letrozole Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PMS-LETROZOLE (DIN 02309114) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
• Apr 27, 2010Letrozole Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SANDOZ LETROZOLE (DIN 02344815) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
• Apr 26, 2010Temsirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-04-26 (see label)openfda
• Mar 15, 2010Thiotepa EMA · EU centralised approved cancer not stated in this recordTEPADINA is indicated, in combination with other chemotherapy medicinal products:- with or without total body irradiation (TBI), as conditioning treatment…ema
• Mar 12, 2010Aminolevulinic Acid FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-03-12 (see label)openfda
• Mar 2, 2010Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-03-02 (see label)openfda
• Mar 2, 2010Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-03-02 (see label)openfda
• Feb 18, 2010Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-02-18 (see label)openfda
• Feb 18, 2010Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-02-18 (see label)openfda
• Feb 10, 2010Clofarabine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as CLOLAR (DIN 02330407) under ATC L01BB06 CLOFARABINE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jan 29, 2010Lapatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2010-01-29 (see label)openfda
• Jan 4, 2010Azacitidine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as VIDAZA (DIN 02336707) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd

RegulatoryAll 2010 records with filters →

Studies

3,680

Interventional

2,955

Phase III

374

Industry-led

953

With posted results

1,048

Countries with sites

95

Published source: clinicaltrials · first_posted_date as posted